CD52 is also the target of the monoclonal antibody alemtuzumab that has shown low anti-tumor activity in DLBCL patients based on a series of 11 relapsed or refractory cases, not characterized for CD52 expression [31]. This evidence concerns the gene CD52 and diffuse large B-cell lymphoma.